Several clinical trials, including IMpassion130, have demonstrated that the expression of PD-L1 (SP142) is the best predictor of the efficacy of atezolizumab in the treatment of locally advanced or metastatic triple-negative breast cancer compared to other antibodies [6–8]. The gene discussed is CD274; the disease is triple-negative breast carcinoma.